



Press release 2017-1-25

Additional information: Leave to Appeal in patent dispute over C-RAD's entitlement to patents granted

C-RAD published a press release on Tuesday 24.1.2017 at 8:30 am CET. C-RAD has decided to provide further background information to this press release.

The appeal court (Patent- och marknadsöverdomstolen) has granted leave to the appeal in the patent dispute between Beamocular and C-RAD. The district court (The Stockholm Patent and Market court) confirmed in its verdict dated October 27, 2016 C-RAD's entitlement and ownership of the invention named "Patient Monitoring Radiation Machines". Beamocular party appealed the verdict.

Leave to appeal is granted in the large majority of appeals in patent cases. The decision to leave grant to the appeal does in itself not indicate how the appeal court will rule after having heard the case on the merits.

The appeal court will try the case based on the same material as in the district court. C-RAD is not aware of any circumstances that change the chances to prevail also in the appeal court. C-RAD's view is that nothing new has happened, and C-RAD's assessment of its chances to successfully defend its right to the invention remains unchanged.

The background to the dispute relates to the ownership of a patent family (one patent application and one patent) which originates from an invention named "Patient Monitoring Radiation Machines", whose inventor Kristofer Maad, via the company Beamocular AB, to which he transferred his right, claims that the invention is not owned or has been transferred to C-RAD Positioning. Kristofer Maad was previously employed at C-RAD but resigned from the company in September 2014.

About C-RAD

C-RAD develops innovative solutions for use in advanced radiation therapy. The C-RAD group offers products and solutions for patient positioning, tumor localization and radiation treatment systems. All product development is conducted in three fully owned subsidiaries: C-RAD Positioning AB, C-RAD Imaging AB and C-RAD Innovation AB, all of which are located in Uppsala, Sweden. Employees currently number 45. C-RAD has established three companies for direct sales: C-RAD Inc. in the US, C-RAD GmbH in Germany and C-RAD WOFE in China. Cyrpa International SPRL, a Franco-Belgian laser company, is a wholly owned subsidiary whose operations are integrated. C-RAD AB is listed on NASDAQ Stockholm.

For more information on C-RAD, please visit www.c-rad.com

For further information:

Tim Thurn, CEO C-RAD AB, Phone +46-18-666930, Email investors@c-rad.com

This information is information that C-RAD AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication at 8:30 am CET on January 25, 2017.